論文

査読有り
2016年2月

Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents

LEUKEMIA RESEARCH
  • Taichi Matsumoto
  • ,
  • Shiro Jimi
  • ,
  • Keisuke Migita
  • ,
  • Yasushi Takamatsu
  • ,
  • Shuuji Hara

41
開始ページ
103
終了ページ
110
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.leukres.2015.12.008
出版者・発行元
PERGAMON-ELSEVIER SCIENCE LTD

Despite the recent development of anti-myeloma drugs, the prognosis of high-risk multiple myeloma remains poor. Therefore, new effective treatment strategies for this disease are needed. It has been reported that high intensity of 18-fluorodeoxyglucose positron emission tomography is high-risk factor in myeloma, suggesting that glucose uptake can be therapeutic target in high-risk myeloma. In this study, we addressed the utility of glucose transporter 1 (GLUT1) as a therapeutic target for myeloma with increased glucose uptake. We found myeloma cell lines with elevated glucose uptake activity via GLUT1 up-regulation. STF-31, a selective GLUT1 inhibitor, completely suppressed the glucose uptake activity and induced apoptosis in GLUT1 expressing myeloma cells. On the other hand, this agent little shows the cytotoxicity in normal peripheral blood mononuclear cells. Moreover, STF-31 synergistically enhanced the cell death induced by melphalan, doxorubicin, and bortezomib. GLUT1 may be promising therapeutic target in myeloma with elevated glucose uptake. (C) 2015 Elsevier Ltd. All rights reserved.

Web of Science ® 被引用回数 : 14

リンク情報
DOI
https://doi.org/10.1016/j.leukres.2015.12.008
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/26790725
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000369236900017&DestApp=WOS_CPL

エクスポート
BibTeX RIS